Atara Biotherapeutics (ATRA) Price to Sales (2021 - 2026)

Atara Biotherapeutics (ATRA) has reported Price to Sales for 6 consecutive years, with 273.93 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Sales rose 5012.96% year-over-year to 273.93; the trailing twelve-month figure through Jun 2026 stood at 27.86 (up 5482.67% YoY), and the FY2025 full-year result was 1.88, up 143.08% from the prior year.
• Price to Sales grew to 273.93 in Q2 2026 per ATRA's latest filing, from 129.08 in the prior quarter.
• Across five years, Price to Sales topped out at 1268.71 in Q4 2022 and bottomed at 0.65 in Q1 2025.
• Historically, Price to Sales has averaged 143.38 across 5 years, with a median of 63.42 in 2023.
• The sharpest annual moves came in 2023 and 2026: Price to Sales tumbled 98.99% in 2023, then jumped 19713.93% in 2026.
• Over 5 years, Price to Sales stood at 1268.71 in 2022, then sank by 98.99% to 12.84 in 2023, then slumped by 76.3% to 3.04 in 2024, then jumped by 4575.43% to 142.27 in 2025, then jumped by 92.55% to 273.93 in 2026.
• According to Business Quant data, Price to Sales over the past three periods registered 273.93, 129.08, and 142.27 for Q2 2026, Q1 2026, and Q4 2025 respectively.